ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares
December 03, 2019 01:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Dec. 03, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has...
ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
December 02, 2019 02:07 ET
|
ASLAN PHARMACEUTICALS LIMITED
- ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study - 3 patients completed 1 month of dosing and achieved average reduction in EASI score of 71%....
ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
October 31, 2019 03:37 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
October 22, 2019 02:45 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability...
ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility
October 18, 2019 03:35 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3...
ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 13, 2019 04:03 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis
June 04, 2019 08:00 ET
|
ASLAN Pharmaceuticals Limited
- Final results from single ascending dose study confirm ASLAN004’s favourable tolerability profile, complete inhibition of downstream mediators and potential for monthly dosing SINGAPORE, June ...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
May 31, 2019 03:15 ET
|
ASLAN Pharmaceuticals Limited
- Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004 SINGAPORE, May 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals...
ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
March 29, 2019 05:50 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, March 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company developing novel therapeutics for global markets, today...
ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
January 29, 2019 17:40 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...